Vaginal Baclofen Suppositories in Chronic Pelvic Pain
Baclofen in Chronic Pelvic Pain, a Randomized, Double-Blind, Placebo Controlled Trial
University of Louisville
44 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate if baclofen vaginal suppositories improve symptoms of Chronic Pelvic Pain (CPP). Participants in this study will take four short questionnaires prior to being randomized. Randomization is like flipping a coin; participants have an equal likelihood of being randomized to the treatment group (vaginal baclofen suppositories) or placebo group (vaginal suppository without baclofen ingredient). Participants will take their assigned treatment nightly for 8 weeks. Follow up visits will be at the 4 and 8 week time frames, when questionnaires will again be completed. Participants may receive additional treatments for CPP during the course of the study. After 8 weeks Participants will be offered a prescription for baclofen suppositories and the study drug will be stopped. Follow up on patient symptoms with questionnaires will again occur at 12 weeks.
Eligibility
Inclusion Criteria3
- Women ages 18-65 years old
- Women are not sexually active, sexually active with same sex partners or are on effective contraception
- Diagnosed with Chronic Pelvic Pain
Exclusion Criteria6
- Gross hematuria
- Currently pregnant or breastfeeding
- Unable to speak and read English
- History of allergic reaction to baclofen tablet
- History of allergic reaction to components of placebo (coconut oil)
- History of gastrointestinal, genitourinary, or pelvic cancer in the last 5 years
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
20 mg baclofen vaginal suppository in Supposibase F daily per vagina - to be compounded by The Louisville Compounding Pharmacy
Vaginal suppository composed of Supposibase F daily per vagina
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05968937